NVAX Novavax Inc.

223.81
+35.24  (+19%)
Previous Close 188.57
Open 206.17
52 Week Low 76.5913
52 Week High 331.68
Market Cap $16,583,075,497
Shares 74,094,435
Float 73,687,058
Enterprise Value $11,749,853,028
Volume 14,505,747
Av. Daily Volume 3,992,013
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
NVX-CoV2373
COVID-19 vaccine
Phase 3
Phase 3
Phase 3 U.S. trial data released June 14, 2021. 90.4% efficacy overall, 100% protection against moderate and severe disease.
NanoFlu vaccine
Influenza
Phase 3
Phase 3
Phase 3 top-line data met primary endpoints - March 24, 2020.
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Phase 3
Phase 3
Phase 3 top-line data released March 28, 2019 - primary endpoint not met. Noted June 10, 2019 that a further Phase 3 trial is required.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3
Phase 3
Phase 3 released September 15, 2016 did not demonstrate efficacy.

Latest News

  1. GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for an additional 100 million doses through 2023.

    Novavax is working to complete its rolling submission for NVX-CoV2373 to the European Medicines Agency (EMA) in the third quarter of 2021, with delivery of initial doses expected to begin following…

    GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for an additional 100 million doses through 2023.

    Novavax is working to complete its rolling submission for NVX-CoV2373 to the European Medicines Agency (EMA) in the third quarter of 2021, with delivery of initial doses expected to begin following approval.

    "We thank the European Commission for their partnership in this important step to expand vaccine options for the citizens of Europe and globally as we work to bring the first COVID-19 protein subunit vaccine to the market," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world."

    In a Phase 3 clinical trial with nearly 30,000 adults in the United States and Mexico, NVX-CoV2373 demonstrated 100% protection against moderate and severe disease and 90.4% overall efficacy. In a Phase 3 clinical trial conducted in the United Kingdom with approximately 15,000 adults, NVX-CoV2373 showed an overall efficacy of 89.7%, and more than 96% efficacy against the original strain of the virus.

    "As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population. It further strengthens our broad vaccine portfolio, to the benefit of Europeans and our partners worldwide," said Ursula von der Leyen, President of the European Commission.

    Novavax' global supply chain spans more than 10 countries, including facilities across the European Union from which it plans to ultimately supply doses.

    About NVX-CoV2373

    NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.

    NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the B.1.1.7 (Alpha) variant and 89.7% overall; and the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall. It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 55% efficacy overall in HIV-negative participants and 48.6% efficacy against a newly emerging escape variant first described in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.

    NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.

    About Matrix-M™ Adjuvant

    Novavax' patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

    For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

    Forward-Looking Statements

    Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Contacts:

    Investors

    Novavax, Inc.

    Erika Schultz | 240-268-2022

    Solebury Trout

    Alexandra Roy | 617-221-9197

    Media

    Alison Chartan | 240-720-7804

    Laura Keenan | 202-709-7521

    Novavax Logo (PRNewsfoto/Novavax)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-and-european-commission-finalize-advance-purchase-agreement-for-up-to-200-million-doses-of-covid-19-vaccine-301348288.html

    SOURCE Novavax, Inc.

    View Full Article Hide Full Article
  2. GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results and operational highlights on Thursday, August 5, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:

    Conference call details:

    Date:

    August 5, 2021

    Time: 

    4:30 p.m. U.S. Eastern Time (ET)

    Dial-in number: 

    (866) 652-5200 (Domestic) or (412) 317-6060 (International) 

    Webcast: 

    www.novavax.com/events

      •  Participants will be prompted to request to join the Novavax, Inc. call.

      •  To ensure a timely connection, it is recommended that participants join at

    GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results and operational highlights on Thursday, August 5, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:

    Conference call details:

    Date:

    August 5, 2021

    Time: 

    4:30 p.m. U.S. Eastern Time (ET)

    Dial-in number: 

    (866) 652-5200 (Domestic) or (412) 317-6060 (International) 

    Webcast: 

    www.novavax.com/events

      •  Participants will be prompted to request to join the Novavax, Inc. call.

      •  To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.



    Replay details:

    Date: 

    Available starting at 7:30 p.m. ET, August 5, 2021

    Dial-in number: 

    (877) 344-7529 (Domestic) or (412) 317-0088 (International)

    Passcode: 

    10158313

    Webcast: 

    www.novavax.com/events, until November 12, 2021

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

    For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

    Contacts:     

    Investors

    Novavax, Inc.

    Erika Schultz | 240-268-2022

    Solebury Trout

    Alexandra Roy | 617-221-9197

    Media

    Alison Chartan | 240-720-7804

    Laura Keenan | 202-709-7521

    Novavax Logo (PRNewsfoto/Novavax)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-and-operational-highlights-on-august-5-2021-301325648.html

    SOURCE Novavax, Inc.

    View Full Article Hide Full Article
  3. GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM). The final analysis confirmed an overall efficacy of 89.7% with over 60% (half) of the cases caused by the B.1.1.7 (Alpha) variant, and a 96.4% efficacy against non-B.1.1.7 (non-Alpha) variants which represents strains most similar to the original virus.

    The manuscript published today in NEJM, 'Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,' provides the final…

    GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM). The final analysis confirmed an overall efficacy of 89.7% with over 60% (half) of the cases caused by the B.1.1.7 (Alpha) variant, and a 96.4% efficacy against non-B.1.1.7 (non-Alpha) variants which represents strains most similar to the original virus.

    The manuscript published today in NEJM, 'Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,' provides the final trial analysis, building on an initial interim analysis conducted in January 2021, and the updated analysis announced in March 2021, while additional data from the study was subsequently shared in preprint server medRxiv in May 2021. Today's publication may be accessed here.

    "We continue to be very encouraged by data showing high levels of efficacy against even mild disease, and that NVX-CoV2373 offers strong cross-protection against both the B.1.1.7 (Alpha) variant and non-B.1.1.7 (non-Alpha) variant strains which are widely circulating," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "This publication also reinforces the reassuring safety and efficacy profile shown in studies of our vaccine to-date and underscores the potential for NVX-CoV2373 to play an important role in solving this ongoing global public health crisis."

    The randomized, observer-blinded, placebo-controlled study, led by researchers at St George's, University of London and St George's Hospital, London, enrolled more than 15,000 adults at trial sites across the United Kingdom. The research demonstrated that a two-dose regimen of Novavax' COVID-19 vaccine candidate conferred 96.4% protection against non-B.1.1.7 (non-Alpha) variant strains and nearly 90% protection against all strains in circulation at that time. It also demonstrated that initial vaccine side effects were mostly mild and transient, and that no imbalance was seen in more serious adverse events compared with the placebo arm. The study assessed efficacy during a period when the B.1.1.7 (Alpha) variant strain of the virus was emerging and circulating widely in the United Kingdom and is the same variant that is currently widespread in the United States.

    "It is quite remarkable how well the vaccine efficacy from our United Kingdom trial matches the results seen in the United States in the recently released PREVENT-19 trial results, giving even more confidence in the potential role of this vaccine in helping to control the pandemic," said Professor Paul Heath, FRCPCH, Vaccine Institute, St George's, University of London and St George's Hospital, London, who is chief investigator of the Novavax United Kingdom trial. "It really highlights the consistent performance of this vaccine in different populations and against a variety of evolving strains."

    About NVX-CoV2373

    NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax' patented saponin-based Matrix-MTM to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.

    NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the B.1.1.7 (Alpha) variant and 89.7% overall; and the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall. It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 55% efficacy overall in HIV-negative participants and 48.6% efficacy against a newly emerging escape variant first described in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.

    NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.

    About Matrix-M™ Adjuvant

    Novavax' patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

    For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

    Forward-Looking Statements

    Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Contacts:

    Investors

    Novavax, Inc.

    Erika Schultz | 240-268-2022

    Solebury Trout

    Alexandra Roy | 617-221-9197

    Media

    Alison Chartan | 240-720-7804

    Laura Keenan | 202-709-7521

    Novavax Logo (PRNewsfoto/Novavax)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-publishes-results-of-united-kingdom-phase-3-clinical-trial-in-new-england-journal-of-medicine-demonstrating-high-levels-of-efficacy-of-covid-19-vaccine-301323714.html

    SOURCE Novavax, Inc.

    View Full Article Hide Full Article
  4. GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Vaccine Forum. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

    Fireside chat details:

    Date:

    Tuesday, June 22, 2021

    Time:

    11:00 – 11:50 a.m. Eastern Time (ET)

    Moderator:

    Geoffrey Porges, M.B.B.S.

    Novavax participants:

    Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer

    Please contact your

    GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Vaccine Forum. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

    Fireside chat details:

    Date:

    Tuesday, June 22, 2021

    Time:

    11:00 – 11:50 a.m. Eastern Time (ET)

    Moderator:

    Geoffrey Porges, M.B.B.S.

    Novavax participants:

    Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer

    Please contact your SVP Leerink representative to view the session.

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

    For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

    Contacts:

    Investors

    Novavax, Inc.

    Erika Schultz | 240-268-2022

    Solebury Trout

    Alexandra Roy | 617-221-9197

    Media

    Alison Chartan | 240-720-7804

    Laura Keenan | 202-709-7521

    Amy Speak | 617-420-2461

    Novavax Logo (PRNewsfoto/Novavax)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-svb-leerink-cyberx-series-vaccine-forum-301315044.html

    SOURCE Novavax, Inc.

    View Full Article Hide Full Article
  5. GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC) meeting, taking place virtually on June 17. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

    Session details are as follows:




    Date:

    Thursday, June 17, 2021

    Time:

    3:15 p.m. – 4:15 p.m. Eastern Time (ET)

    Title:

    Experiences in the Field: COVID-19 Vaccine Authorization and Beyond

    Novavax Participant:

    Gregory

    GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC) meeting, taking place virtually on June 17. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

    Session details are as follows:







    Date:

    Thursday, June 17, 2021

    Time:

    3:15 p.m. – 4:15 p.m. Eastern Time (ET)

    Title:

    Experiences in the Field: COVID-19 Vaccine Authorization and Beyond

    Novavax Participant:

    Gregory M. Glenn, M.D., President, Research and Development

    For more information or to register for the meeting, visit: https://www.hhs.gov/webforms/nvac/index.html.

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

    For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

    Contacts:

    Investors

    Novavax, Inc.

    Erika Schultz | 240-268-2022

     

    Solebury Trout

    Alexandra Roy | 617-221-9197

     

    Media

    Alison Chartan | 240-720-7804

    Laura Keenan | 202-709-7521

    Novavax Logo (PRNewsfoto/Novavax)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-national-vaccine-advisory-committee-meeting-301314763.html

    SOURCE Novavax, Inc.

    View Full Article Hide Full Article
View All Novavax Inc. News